Literature DB >> 2859069

Zopiclone: a non-benzodiazepine hypnotic. Controlled comparison to temazepam in insomnia.

D Wheatley.   

Abstract

Zopiclone, a non-benzodiazepine hypnotic, was compared with temazepam in the treatment of 36 patients suffering from insomnia; the trial period was two weeks, with cross-over of medications at one week and a randomised order of administration. There were highly significant improvements with both drugs, as compared to the control period in respect of: sleep latency, number of times waking during the night, and quality and duration of sleep. The incidence of side-effects was very low. No significant between-drug differences were found in respect to any of the assessment measures or of the incidence of side-effects.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859069     DOI: 10.1192/bjp.146.3.312

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  6 in total

Review 1.  Prescribing short-acting hypnosedatives. Current recommendations from a safety perspective.

Authors:  D Wheatley
Journal:  Drug Saf       Date:  1992 Mar-Apr       Impact factor: 5.606

Review 2.  Stress and illness.

Authors:  D Wheatley
Journal:  Occas Pap R Coll Gen Pract       Date:  1993-08

3.  Meta-analysis of benzodiazepine use in the treatment of insomnia.

Authors:  A M Holbrook; R Crowther; A Lotter; C Cheng; D King
Journal:  CMAJ       Date:  2000-01-25       Impact factor: 8.262

Review 4.  Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic.

Authors:  K L Goa; R C Heel
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

Review 5.  A comparative assessment of the risks and benefits of zopiclone: a review of 15 years' clinical experience.

Authors:  G Hajak
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.228

6.  Eszopiclone: its use in the treatment of insomnia.

Authors:  Jaime M Monti; S R Pandi-Perumal
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.